Comparison of serum BDNF levels in deficit and nondeficit chronic schizophrenia and healthy controls

Psychiatry Research

Volumn 220, Issue 1-2, 2014, Pages 197-200

  Valiente Gómez, Alicia ^a,b   Amann, Benedikt L ^a,b   Mármol, Frederic ^c   Oliveira, Cristina ^d   Messeguer, Ana ^d   Lafuente, Amalia ^b,c,e   Pomarol Clotet, Edith ^a,b   Bernardo Arroyo, Miguel ^b,c,d,e  

^a FIDMAG GERMANES HOSPITALÀRIES RESEARCH FOUNDATION   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Antipsychotic treatment; BDNF; Deficit schizophrenia; Neurotrophines

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOMIPRAMINE; FLUPHENAZINE; PROLACTIN; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROXY FOR THE DEFICIT SYNDROME SCALE; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; BLOOD; CLASSIFICATION; MIDDLE AGED; YOUNG ADULT;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84908219170     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.08.039     Document Type: Article

References (34)

1. Angelucci F., Ricci V., Gelfo F., Martinotti G., Brunetti M., Sepede G., Signorelli M., Aguglia E., Pettorruso M., Vellante F., Di Giannantonio M., Caltagirone C. BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure. Brain and Cognition 2013, 84:118-122.
2. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews 2012, 64:238-258.
3. Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. The EMBO Journal 1982, 1:549-553.
4. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
5. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. The American Journal of Psychiatry 1988, 145:578-583.
6. Cohen A.S., Brown L.A., Minor K.S. The psychiatric symptomatology of deficit schizophrenia: a meta-analysis. Schizophrenia Research 2010, 118:122-127.
7. Durany N., Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. European Psychiatry 2004, 19:326-337.
8. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters 2007, 420:45-48.
9. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Molecular Psychiatry 2011, 16:960-972.
10. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. Journal of Psychiatric Research 2007, 41:31-35.
11. Huang T.L., Lee C.T. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. Journal of Psychiatric Research 2006, 40:664-668.
12. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
13. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience Letters 2002, 328:261-264.
14. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
15. Kirkpatrick B., Buchanan R.W., Breier A., Carpenter W.T. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Research 1993, 47:47-56.
16. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Archives of General Psychiatry 2001, 58:165-171.
17. Kirkpatrick B., Fernandez-Egea E., Garcia-Rizo C., Bernardo M. Differences in glucose tolerance between deficit and nondeficit schizophrenia. Schizophrenia Research 2009, 107:122-127.
18. Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., Schuff-Werner P., Virchow J.C. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiology Aging 2005, 26:115-123.
19. Martinotti G., Di Iorio G., Marini S., Ricci V., De Berardis D., Di Giannantonio M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. Journal of Biological Regulators and Homeostatic Agents 2012, 26:347-356.
20. Mondelli V., Cattaneo A., Belvederi Murri M., Di Forti M., Handley R., Hepgul N., Miorelli A., Navari S., Papadopoulos A.S., Aitchison K.J., Morgan C., Murray R.M., Dazzan P., Pariante C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. The Journal of Clinical Psychiatry 2011, 72:1677-1684.
21. Niitsu T., Shirayama Y., Matsuzawa D., Hasegawa T., Kanahara N., Hashimoto T., Shiraishi T., Shiina A., Fukami G., Fujisaki M., Watanabe H., Nakazato M., Asano M., Kimura S., Hashimoto K., Iyo M. Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry 2011, 35:1836-1840.
22. Palomino A., Gonzalez-Pinto A., Martinez-Cengotitabengoa M., Ruiz de Azua S., Alberich S., Mosquera F., Matute C. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Progress in Neuro-psychopharmacology & Biological Psychiatry 2013, 44:29-33.
23. Pluchino N., Russo M., Santoro A.N., Litta P., Cela V., Genazzani A.R. Steroid hormones and BDNF. Neuroscience 2013, 239:271-279.
24. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2006, 361:1545-1564.
25. Reis H.J., Nicolato R., Barbosa I.G., Teixeira do Prado P.H., Romano-Silva M.A., Teixeira A.L. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neuroscience Letters 2008, 439:157-159.
26. Rizos E.N., Rontos I., Laskos E., Arsenis G., Michalopoulou P.G., Vasilopoulos D., Gournellis R., Lykouras L. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry 2008, 32:1308-1311.
27. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., Katsafouros K., Lykouras L. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. The World Journal of Biological Psychiatry 2010, 11:251-255.
28. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neuroscience Letters 2003, 351:111-114.
29. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Research 2002, 110:249-257.
30. Vinogradov S., Fisher M., Holland C., Shelly W., Wolkowitz O., Mellon S.H. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biological Psychiatry 2009, 66:549-553.
31. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of Clinical Psychiatry 2003, 64:663-667.
32. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., Chen da C., Kosten T.R., Zhang X.Y. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Progress in Neuro-psychopharmacology & Biological Psychiatry 2009, 33:1508-1512.
33. Yang Y.Q., Sun S., Yu Y.Q., Li W.J., Zhang X., Xiu M.H., Chen da C., De Yang F., Liu H., Li C., Kosten T.R., Zhang X.Y. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neuroscience Letters 2011, 502:37-40.
34. Zhang X.Y., Liang J., Chen da C., Xiu M.H., Yang F.D., Kosten T.A., Kosten T.R. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology 2012, 222:277-284.